pacemaker, implantable inversion recovery pulse) 4.2 years; defibrillator and intracerebral sequence LVEF (Echo) = 30 ± 9%; aneurysm clips LVEF (CMR) = 23 ± 10; Contrast agent: 0.2 mmol/kg medications: ACE inhibitor/ARB = 43%, Time delay: 10 minutes = 27% LV function: Not reported Mean follow up: 406 ± 241 days for LGE+ and 425 ± LGE diagnosis: All areas of LGE 174 days for LGE– patients were independently traced by 2 cardiologists who were blinded to the clinical history of the patients. Patients were classified as having advanced LGE when %LGE was ≥10%, and non-advanced LGE when %LGE was <10%. Wang et al. Prospective N=63 consecutive patients Inclusion criteria: Scanner: 1.5-T scanner ICD implantation: Not described () cohort diagnosed with DCM: consecutive patients Cardiac function sequence: Outcomes: diagnosed with DCM from n=31 (49%) LGE+ Breath-hold retrospective October 2009 to April 2013 HR for likelihood of having a: n=32 (51%) LGE– cine true-FISP (fast imaging China NHMRC level II Exclusion criteria: patients with steady-state precession) cardiac death (HF) Patient characteristics: with severe valvular disease, sequence to acquire contiguous cardiac transplantation active myocarditis, short-axis images. age = 53.9 ± 11.5 years; SIGN: acceptable in LGE+ patients compared with those hypertensive heart disease, LGE sequence: Not reported quality with a male = 70%; that are LGE– tachycardia-induced CM, moderate risk of arrhythmogenic RV CM, Contrast agent: Not reported history of VF or sustained VT bias infiltrative CM, HCM, = 5%; Time delay: Not reported diabetes mellitus, alcohol history of AF = 25%; abuse, persistent AF, metal LV function: The LVEF and fragments in the body, RVEF were calculated using LBBB = 17%; implanted ferromagnetic Simpson’s rule. LVEF (CMR) = 24.4 ± 8.5%; devices or otherwise
4.2 years; LVEF (Echo) = 30 ± 9%; LVEF (CMR) = 23 ± 10; medications: ACE inhibitor/ARB = 43%, = 27% Mean follow up: 406 ± 241 days for LGE+ and 425 ± 174 days for LGE– patients pacemaker, implantable defibrillator and intracerebral aneurysm clips inversion recovery pulse) sequence Contrast agent: 0.2 mmol/kg Time delay: 10 minutes LV function: Not reported LGE diagnosis: All areas of LGE were independently traced by 2 cardiologists who were blinded to the clinical history of the patients. Patients were classified as having advanced LGE when %LGE was ≥10%, and non-advanced LGE when %LGE was <10%. Wang et al. () China Prospective cohort NHMRC level II SIGN: acceptable quality with a moderate risk of bias N=63 consecutive patients diagnosed with DCM: n=31 (49%) LGE+ n=32 (51%) LGE– Patient characteristics: age = 53.9 ± 11.5 years; male = 70%; history of VF or sustained VT = 5%; history of AF = 25%; LBBB = 17%; LVEF (CMR) = 24.4 ± 8.5%; Inclusion criteria: consecutive patients diagnosed with DCM from October 2009 to April 2013 Exclusion criteria: patients with severe valvular disease, active myocarditis, hypertensive heart disease, tachycardia-induced CM, arrhythmogenic RV CM, infiltrative CM, HCM, diabetes mellitus, alcohol abuse, persistent AF, metal fragments in the body, implanted ferromagnetic devices or otherwise Scanner: 1.5-T scanner Cardiac function sequence: Breath-hold retrospective cine true-FISP (fast imaging with steady-state precession) sequence to acquire contiguous short-axis images. LGE sequence: Not reported Contrast agent: Not reported Time delay: Not reported LV function: The LVEF and RVEF were calculated using Simpson’s rule. ICD implantation: Not described Outcomes: HR for likelihood of having a: cardiac death (HF) cardiac transplantation in LGE+ patients compared with those that are LGE–
1393-CMRforDCM.docx